Phase II Study of Sipuleucel-T and Indoximod for Patients With Refractory Metastatic Prostate Cancer
Trial · NCT01560923
Results by group36
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 36
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Immune Response to Sipuleucel-T | Sipuleucel-T + Placebo | 29.6 | 95% Confidence Interval 4.86 to 180.37 | Spots per ml | |
| Immune Response to Sipuleucel-T | Sipuleucel-T + Oral Indoximod | 25.45 | 95% Confidence Interval 2.92 to 222.12 | Spots per ml | |
| Number of Participants With Progression Free Survival at 6 Months | Sipuleucel-T + Placebo | 6 | Participants | ||
| Number of Participants With Progression Free Survival at 6 Months | Sipuleucel-T + Oral Indoximod | 11 | Participants | ||
| Objective Response Rate | Sipuleucel-T + Placebo | Partial response (PR) | 1 | Participants | |
| Objective Response Rate | Sipuleucel-T + Oral Indoximod | Partial response (PR) | 0 | Participants | |
| Objective Response Rate | Sipuleucel-T + Placebo | Not Evaluable | 0 | Participants | |
| Objective Response Rate | Sipuleucel-T + Oral Indoximod | Not Evaluable | 2 | Participants | |
| Objective Response Rate | Sipuleucel-T + Placebo | Stable Disease (SD) | 5 | Participants | |
| Objective Response Rate | Sipuleucel-T + Oral Indoximod | Stable Disease (SD) | 11 | Participants | |
| Objective Response Rate | Sipuleucel-T + Placebo | Baseline | 3 | Participants | |
| Objective Response Rate | Sipuleucel-T + Oral Indoximod | Baseline | 1 | Participants | |
| Objective Response Rate | Sipuleucel-T + Placebo | Non-CR/Non-PD | 1 | Participants | |
| Objective Response Rate | Sipuleucel-T + Oral Indoximod | Non-CR/Non-PD | 1 | Participants | |
| Objective Response Rate | Sipuleucel-T + Placebo | Progressive Disease (PD) | 12 | Participants | |
| Objective Response Rate | Sipuleucel-T + Oral Indoximod | Progressive Disease (PD) | 7 | Participants | |
| Objective Response Rate | Sipuleucel-T + Placebo | Not Assessed | 2 | Participants | |
| Objective Response Rate | Sipuleucel-T + Oral Indoximod | Not Assessed | 0 | Participants | |
| Overall Survival | Sipuleucel-T + Placebo | 18 | Participants | ||
| Overall Survival | Sipuleucel-T + Oral Indoximod | 17 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01560923/results